ACTU Stock Forecast & Price Target

Actuate Therapeutics is viewed favorably because oral elraglusib could materially improve the drug’s exposure profile versus the IV formulation, and prior Phase 2 mPDAC data showed a stronger survival benefit in the ~60% of patients with higher exposure (HR 0.48; p<0.001) than in the overall cohort (HR 0.62; p=0.02). The company has FDA clearance for a Phase 1/2 study expected to start in 2H26, with PK/exposure data and a potential RP2D expected in 2H27, while preclinical work in RAS inhibitor combinations may further broaden its utility. Its pediatric neuroblastoma program adds optionality through BEACON2, where a rare pediatric disease PRV could be worth about $150M to $200M, and the rNPV framework still supports value despite funding and dilution risks.

Actuate Therapeutics is facing a weak fundamental setup because it remains pre-revenue while continuing to post sizable losses, including a net loss of $0.20 per diluted share in 2Q26 and $0.24 in 1Q26. Its cash position also deteriorated from $8.1M at the end of 1Q26 to $4.44M at the end of 2Q26, and management believes that balance is not sufficient to fund operations beyond September 2026. With projected 2026 losses of $0.61 to $0.84 per diluted share and no revenue stream, the company appears highly dependent on future financing rather than operating performance.